KRAS and cancer: While anti-EGFR drugs aim to inhibit mCRC cells, cancer may adapt, developing resistance mutations such as those in downstream oncogenes KRAS, NRAS, and BRAF. As sensitive cancer cells are reduced upon treatment, these mutant cells may continue to grow driving tumor progression.